A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

被引:11
作者
Katz, P. O. [1 ]
Johnson, D. A. [2 ]
Levine, D. [3 ]
Rohss, K. [4 ]
Junghard, O. [4 ]
Astrand, M. [4 ]
Nagy, P. [4 ]
机构
[1] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] AstraZeneca Pharmaceut LP, Wilmington, DE USA
[4] AstraZeneca R&D, Molndal, Sweden
关键词
ESOMEPRAZOLE; 40; MG; LANSOPRAZOLE; 30; RANDOMIZED CONTROLLED-TRIAL; SEVERE EROSIVE ESOPHAGITIS; OMEPRAZOLE; 20; BARRETTS-ESOPHAGUS; INTRAGASTRIC PH; DISEASE; SYMPTOMS; PANTOPRAZOLE;
D O I
10.1111/j.1365-2036.2010.04367.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background In patients with Los Angeles (LA) grade C or D oesophagitis, a positive relationship has been established between the duration of intragastric acid suppression and healing. Aim To determine whether there is an apparent optimal time of intragastric acid suppression for maximal healing of reflux oesophagitis. Methods Post hoc analysis of data from a proof-of-concept, double-blind, randomized study of 134 adult patients treated with esomeprazole (10 or 40 mg od for 4 weeks) for LA grade C or D oesophagitis. A curve was fitted to pooled 24-h intragastric pH (day 5) and endoscopically assessed healing (4 weeks) data using piecewise quadratic logistic regression. Results Maximal reflux oesophagitis healing rates were achieved when intragastric pH > 4 was achieved for approximately 50-70% (12-17 h) of the 24-h period. Acid suppression above this threshold did not yield further increases in healing rates. Conclusion After 4 weeks' acid-suppressive therapy for LA grade C or D oesophagitis, successful healing appears to reach a threshold above which improvements are unlikely to be achieved despite an increase in number of hours with intragastric pH > 4.
引用
收藏
页码:443 / 447
页数:5
相关论文
共 26 条
  • [1] Gastric pH - the most relevant predictor of benefit in reflux disease?
    Armstrong, D
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 19 - 26
  • [2] APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE
    BELL, NJV
    BURGET, D
    HOWDEN, CW
    WILKINSON, J
    HUNT, RH
    [J]. DIGESTION, 1992, 51 : 59 - 67
  • [3] Castell DO, 2002, AM J GASTROENTEROL, V97, P575
  • [4] DENT J, 1994, SCAND J GASTROENTE S, V201, P55
  • [5] A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
    Dent, John
    Kahrilas, Peter J.
    Hatlebakk, Jan
    Vakil, Nimish
    Denison, Hans
    Franzen, Stefan
    Lundborg, Per
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (01) : 20 - 26
  • [6] Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
    Fennerty, MB
    Johanson, JF
    Hwang, C
    Sostek, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 455 - 463
  • [7] Importance of pH control in the management of GERD
    Hunt, RH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (07) : 649 - 657
  • [8] HUNT RH, 1995, ALIMENT PHARM THERAP, V9, P3
  • [9] SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE
    JOHNSSON, F
    JOELSSON, B
    GUDMUNDSSON, K
    GREIFF, L
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1987, 22 (06) : 714 - 718
  • [10] American Gastroenterological Association institute technical review on the management of gastroesophageal reflux disease
    Kahrilas, P. J.
    Shaheen, N. J.
    Vaezi, M.
    [J]. GASTROENTEROLOGY, 2008, 135 (04) : 1392 - 1413